Network analysis as a grand unifier in biomedical data science
P McGillivray, D Clarke, W Meyerson… - Annual Review of …, 2018 - annualreviews.org
Biomedical data scientists study many types of networks, ranging from those formed by
neurons to those created by molecular interactions. People often criticize these networks as …
neurons to those created by molecular interactions. People often criticize these networks as …
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on unipolar nonpsychotic depression
CI Giakoumatos, D Osser - Harvard review of psychiatry, 2019 - journals.lww.com
Background The Psychopharmacology Algorithm Project at the Harvard South Shore
Program presents evidence-based recommendations considering efficacy, tolerability …
Program presents evidence-based recommendations considering efficacy, tolerability …
Short and long-term treatment outcomes of stepwise psychopharmacotherapy based on early clinical decision in patients with depressive disorders
Background To investigate the effects of stepwise pharmacotherapy based on early clinical
decision-making on short-and long-term treatment outcomes in outpatients with depressive …
decision-making on short-and long-term treatment outcomes in outpatients with depressive …
[HTML][HTML] Long-term efficacy and tolerability of adjunctive aripiprazole for major depressive disorder: systematic review and meta-analysis
A Seshadri, ME Wermers, TJ Habermann… - The Primary Care …, 2021 - psychiatrist.com
Objective: To assess the long-term efficacy and safety of aripiprazole as an augmentation
strategy for major depressive disorder (MDD). Data Sources: Ovid MEDLINE, PsycInfo, and …
strategy for major depressive disorder (MDD). Data Sources: Ovid MEDLINE, PsycInfo, and …
Beyond cardiovascular medicine: potential future uses of icosapent ethyl
The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapentaenoic
acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree …
acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree …
[HTML][HTML] Antidepressant efficacy and side effect burden: an updated guide for clinicians
T Kutzer, M Dick, T Scudamore, M Wiener… - Drugs in …, 2020 - ncbi.nlm.nih.gov
Antidepressant treatment has been evolving and changing since the 1950s following the
discovery of the classic antidepressant treatments including tricyclic antidepressants and …
discovery of the classic antidepressant treatments including tricyclic antidepressants and …
Rethinking the medication management of major depression
Introduction Current treatment of major depressive disorder (MDD) warrants critical
reexamination. Initial treatment response rates are modest and drop dramatically after 3 …
reexamination. Initial treatment response rates are modest and drop dramatically after 3 …
[PDF][PDF] Thoughtful prescribing for patients with difficult-to-treat depression
A Soubolsky, J Visentin, A Crawley - Canadian Family Physician, 2023 - cfp.ca
Approximately 1 in 20 Canadians are diagnosed with it each year, and it is the second
highest cause of disability worldwide. 1 Nonresponse to treatment is common, with response …
highest cause of disability worldwide. 1 Nonresponse to treatment is common, with response …
Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review
G Perna, S Dacco, A Alciati, F Cuniberti… - Progress in Neuro …, 2021 - Elsevier
Childhood maltreatment (CM) is a predictor of poor outcome across treatments for major
depressive disorder (MDD), while its potential role as a predictor of differential responses to …
depressive disorder (MDD), while its potential role as a predictor of differential responses to …
Emulating a target trial of dynamic treatment strategies for major depressive disorder using data from the STAR∗ D randomized trial
AG Szmulewicz, KN Wanis, RH Perlis… - Biological …, 2023 - Elsevier
Background Clinical guidelines recommend adding a second drug for patients with major
depressive disorder who have a partial response and switching antidepressants for those …
depressive disorder who have a partial response and switching antidepressants for those …